Book a meeting
DO-BO

How Are UK NICE and US IRA/MFN Rewriting Global Pharma Pricing, Sreeram Ramagopalan?

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly rewriting the rules for global launch sequencing and pricing strategy.

They discuss why the US is no longer an isolated “free pricing” island, how UK and EU prices can now feed back into US revenues, and why small and mid‑size biotechs, in particular, can no longer afford to treat US and ex‑US strategies as separate worlds.

If you’re in pharma/biotech, pricing & market access or RWE, and you’re not yet stress‑testing your global evidence, price floors and launch plan against MFN and NICE reforms, this episode is your wake‑up call.

https://www.linkedin.com/feed/update/urn:li:activity:7437804838232453120/

Related

How Do You Build a High-Performing Team in Pharma, Dr. Maurice Kléber?

By

Stefan Walzer

In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Maurice Kléber to explore what building a winning team really takes — drawing on 18 years of leadership and a shared love of ice hockey. They discuss why trust and psychological safety are the foundation of any high-performing […]

Where Does AI Really Add Value in Market Access, Dr. Seye Abogunrin?

By

Stefan Walzer

Everyone wants AI to click the button for them — the real question is whether you still need to click it at all. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Seye Abogunrin, a health economist at Roche, Switzerland, to move AI in market access from […]

Why Should Early Health Economics Move Upstream, Dr. Björn Schwander & Julie Frappier?

By

Stefan Walzer

By the time most health economists get pulled in, the recipe is already set. In this episode of MAP — the Market Access Podcast, Dr. Stefan Walzer sits down with two industry veterans — Dr. Björn Schwander, Founder of AHEAD GmbH and a specialist in early health economic modeling, and Julie Frappier, senior health economist […]